Urgent surgery for RD gives best post-op VA

Article

Urgent vitrectomy/phacovitrectomy to treat retinal detachment will produce the best postoperative visual acuity when it is conducted within 2 days or less of the detachment, according to a recent study.

Urgent vitrectomy/phacovitrectomy to treat retinal detachment will produce the best postoperative visual acuity when it is conducted within 2 days or less of the detachment (RD), according to a study in the Asia-Pacific Journal of Ophthalmology.

Researchers conducted a retrospective, noncomparative, interventional case series of 56 eyes with macula-on RD and 126 eyes with bullous macula-off RD.

When the duration of macula detachment was 2 days or less, approximately 90% of eyes achieved a postoperative 20/40 best-corrected visual acuity (BCVA). Between 2 and 10 days, the ratio of eyes achieving BCVA of 20/40 decreased (P = 0.008), plateauing around 40%. Mean BCVA showed a statistically significant decrease when the time from the RD to the vitrectomy/phacovitrectomy exceeded 10 days (P = 0.009).

"An increasing number of ophthalmologists are using vitrectomy as the first line of treatment for retinal detachment," the researchers said. "To achieve a good postoperative visual acuity, urgent surgery with a duration of macular detachment of 2 days or less is desired. Operative repair within this period, rather than outright emergency surgery, may be appropriate for most cases."

To view the abstract of this study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.